/
JAMA Pediatrics  Journal Club Slides: JAMA Pediatrics  Journal Club Slides:

JAMA Pediatrics Journal Club Slides: - PowerPoint Presentation

eatsui
eatsui . @eatsui
Follow
347 views
Uploaded On 2020-06-29

JAMA Pediatrics Journal Club Slides: - PPT Presentation

Total Serum Bilirubin Levels at or Above the ETT Wu YW Kuzniewicz MW Wickremasinghe AC et al Risk of cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold a populationbased study ID: 788981

infants tsb ett levels tsb infants levels ett risk kernicterus consistent study level exposed cohort results based guidelines factors

Share:

Link:

Embed:

Download Presentation from below link

Download The PPT/PDF document "JAMA Pediatrics Journal Club Slides:" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.


Presentation Transcript

Slide1

JAMA Pediatrics Journal Club Slides:Total Serum Bilirubin Levels at orAbove the ETT

Wu YW, Kuzniewicz MW, Wickremasinghe AC, et al.

Risk of cerebral palsy in infants with total serum bilirubin levels at or above the exchange transfusion threshold: a population-based study

.

JAMA Pediatr

.

Published online January 5, 2015. doi

:10.1001/jamapediatrics.2014.3036.

Slide2

BackgroundExchange transfusion is recommended for newborns with total serum bilirubin (TSB) levels thought to place them at risk for

cerebral palsy (CP

).The excess risk of CP among these infants is unknown.Study ObjectiveTo quantify the risks of CP and CP consistent with kernicterus that are associated with high TSB levels based on the 2004 American Academy of Pediatrics exchange transfusion threshold (ETT) guidelines.

Introduction

Slide3

Study Design

Double-cohort study

nested within the Late Impact of Getting Hyperbilirubinemia or Phototherapy (LIGHT) birth cohort.SettingKaiser Permanente Northern California.PatientsTwo cohorts sampled from a population of all 525 409 infants born at ≥5 weeks’ gestation at Kaiser Permanente Northern California from January 1,

1995, through December 31, 2011.

Exposed cohort: All 1833 infants with ≥1 TSB measurement at or above the ETT based on age at testing, gestational age, and results of direct antiglobulin testing.Unexposed cohort: 20% random sample of infants with all TSB levels below the ETT.

Methods

Slide4

Methods

Outcomes

CP: nonprogressive congenital motor dysfunction with hypertonia or dyskinesia (choreoathetosis or dystonia) CP consistent with kernicterus: bilateral globus pallidus injury in the setting of dyskinetic CP.Limitations Measured maximum TSB levels are only estimates of

true

peak levels.CP diagnosis relied on clinical records (ie, patients not examined for study).Brain magnetic resonance imaging performed at different ages without a standard protocol.Absolute risk differences for extreme levels of hyperbilirubinemia were calculated based on small numbers of exposed

infants,

thus generating wide confidence

intervals

.

Slide5

Results1833 of 525 409

infants

(0.3%) were exposed to ≥1 TSB level at or above the ETT.Exposed infants were more likely to be male, Asian, and preterm. CP diagnosed in 7 of 1833 infants (0.4%) exposed to a TSB level at or above the ETT compared with 86 of 104 716 unexposed infants (0.1%) (relative risk,

4.7 [95

% CI, 2.2-10.0]; P < .001).Risk of CP was highest for infants with most severe elevations of TSB levels.No difference between the degree of elevation in TSB levels above the ETT and

the peak

TSB

levels

in ability to predict hypertonic/dystonic

CP (areas under the receiver operating characteristic curve, 0.71 vs 0.70;

P

= .79).

Slide6

Selection of Infants With CP Within the 2 Study Cohorts

Results

Slide7

Results

Characteristics of Infants With and Without a TSB Level Above the EET

Slide8

Results

Risk for CP Associated With Varying Elevated TSB Levels

Slide9

Results7 infants had CP and

a

TSB Level Above the ETT3 had CP consistent with kernicterus (ie, T2 hyperintensity in bilateral globus pallidus, and dyskinetic CP).4 had other causes of CP.

Incidence of CP consistent with kernicterus

was 0.57 per 100 000 births.All 3 infants with CP consistent with kernicterus had both of the following:TSB level >5 mg/dL above the ETT.≥2 risk factors for neurotoxicity (ie, prematurity,

glucose-6-phosphate dehydrogenase [G6PD]

deficiency, hypoalbuminemia,

hypoxia-

ischemia,

and/or

sepsis).

Slide10

Results

Clinical Characteristics of 7 Infants With CP Who Were Exposed to a TSB Level Above the ETT

Slide11

CommentThe 2004

American Academy of Pediatrics ETT

guidelines effectively identified all cases of CP consistent with kernicterus in a large population. Incidence of CP due to kernicterus in United States:Study’s estimate (0.57 per 100 000 births) falls within the range

of previously reported estimates (

0.4-2.7 per 100 000 births).All 3 patients with CP consistent with kernicterus had peak TSB levels >5 mg/dL above the ETT as well as ≥2 neurotoxicity risk factors.Although maximum TSB levels up to 5 mg/dL above the ETT were almost always benign, infants with such levels

should

not

be excluded from treatment. Infants

with maximum TSB levels up to 5 mg/dL above the ETT

may have good outcomes

precisely because they were treated and their TSB levels were prevented from

increasing.

Slide12

CommentCP consistent with kernicterus was rare in this modern cohort of term and late preterm

infants and

did not occur in a single infant with hyperbilirubinemia who was otherwise healthy with no neurotoxicity risk factors present, regardless of the severity of elevation of the TSB level.Findings support the suggestion that infants with hyperbilirubinemia without neurotoxicity risk factors may have a higher tolerance than recognized in current management guidelines.These data, along with estimates of risks and costs of treatment, should be considered when developing future updated guidelines for management of jaundice in term and late preterm newborns.

Slide13

If you have questions, please contact the corresponding author:Yvonne

W. Wu

, MD, MPH, Department of Neurology, University of California, San Francisco, 675 Nelson Rising Ln, Ste 411, San Francisco, CA 94158 (wuy@ucsf.edu).Funding/SupportThis study was supported by

grant

R01HS020618 from the Agency for Healthcare Research and Quality.Conflict of Interest DisclosuresDrs Wu and Newman have provided expert consultation on cases related to CP and/or kernicterus. No other disclosures were reported.

Contact Information